Stop TB Partnership

ImmBio enters into co-development agreement with China for TB vaccine

11 October 2012 - Cambridge, UK - Vaccine developer ImmBio has entered into a research, co-development and license arrangement with the Lanzhou Institute of Biological Products (LIBP), part of the China National Biotech Group.

Under the arrangement, ImmBio and LIBP will develop a vaccine against tuberculosis, T-BioVax^TM, carry out human clinical trials and collaborate on manufacturing and sales.

"I am delighted to be working with such a prestigious organisation as LIBP in the development of our tuberculosis vaccine and am confident that the improved efficacy of our platform technology will be clearly demonstrated through the proposed human trials," said Graham Clarke, chief executive of ImmBio.

ImmBio has previously been supported by the UK government and the Bill & Melinda Gates Foundation, through Aeras.